login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
CHEMOCENTRYX INC (CCXI) Stock News
USA
- NASDAQ:CCXI -
US16383L1061
-
Common Stock
51.99
USD
+0.03 (+0.06%)
Last: 10/19/2022, 8:04:24 PM
51.99
USD
0 (0%)
After Hours:
10/19/2022, 8:04:24 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
CCXI Latest News, Press Relases and Analysis
All
Press Releases
3 years ago - By: Benzinga
- Mentions:
AMGN
JNJ
SNY
HZNP
Two Down With Sanofi Bowing Out From Horizon Buyout Talks, Amgen Agrees To Buy For $116.5/Share
3 years ago - By: Benzinga
- Mentions:
BIIB
NBIX
NVAX
VRTX
...
How to Trade the High-Growth Biotech Sector in the Midst of a Bear Market
3 years ago - By: Amgen
- Mentions:
AMGN
AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX
3 years ago - By: ChemoCentryx, Inc.
ChemoCentryx Announces Presentations at the 2022 American Society of Nephrology and American College of Rheumatology Annual Meetings
3 years ago - By: ChemoCentryx, Inc.
ChemoCentryx Announces Upcoming Presentations for Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting
3 years ago - By: Investor's Business Daily
- Mentions:
XBI
CPRX
AERI
VRNA
...
Here Are 10 Biotech Stocks — Including Catalyst And Viridian — That Would Have Netted You $10,000 More This Year
3 years ago - By: Investor's Business Daily
- Mentions:
CPRX
BMRN
VRTX
SRPT
...
Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin
3 years ago - By: Scott+Scott Attorneys at Law LLP
INVESTIGATION ALERT: Scott+Scott Attorneys at Law LLP Investigates ChemoCentryx, Inc.’s Directors and Officers for Breach of Fiduciary Duties – CCXI
3 years ago - By: InvestorPlace
- Mentions:
AXP
AMGN
CAT
CVX
...
7 Dow Stocks With Superior Fundamentals
3 years ago - By: Scott+Scott Attorneys at Law LLP
INVESTIGATION ALERT: Scott+Scott Attorneys at Law LLP Investigates ChemoCentryx, Inc.’s Directors and Officers for Breach of Fiduciary Duties – CCXI
3 years ago - By: Investor's Business Daily
- Mentions:
PFE
BMY
ALNY
KRTX
...
10 Biotech Stocks Are Up 40% Or More This Year, Including Karuna, Axsome And Others
3 years ago - By: ChemoCentryx, Inc.
ChemoCentryx Announces TAVNEOS® (avacopan) Presentations at Upcoming Medical Conferences
3 years ago - By: Investor's Business Daily
- Mentions:
ALC
AERI
BMY
AMGN
...
Blistering-Hot Biotech Shopping Spree Continues: Alcon To Buy Aerie For $770 Million
3 years ago - By: ChemoCentryx, Inc.
ChemoCentryx Cancels Second Quarter 2022 Financial Results Conference Call
3 years ago - By: Investor's Business Daily
- Mentions:
AAPL
REGN
MRNA
RGEN
...
Stock Market Rally Mixed As Oil Prices Fall, Job Growth Hot: Weekly Review
Please enable JavaScript to continue using this application.